Why
Liposomal
Amphotericin
B
Liposomal
Amphotericin
B
Why Liposomal Amphotericin B
I Am… Liposomal Amphotericin B: Ready to take
on Ibrahim's Aspergillus infection6,7
on Ibrahim's Aspergillus infection6,7
Liposomal Amphotericin B was chosen to help
treat Ibrahim's life-threatening fungal infection
because it demonstrates:
treat Ibrahim's life-threatening fungal infection
because it demonstrates:
Efficacy as a first-line antifungal therapy
Liposomal Amphotericin B can be used for proven
or probable invasive aspergillosis or other mould
infections (EORTC/MSG criteria) in a variety of
at-risk patients, including those who are critically
ill.8,9
or probable invasive aspergillosis or other mould
infections (EORTC/MSG criteria) in a variety of
at-risk patients, including those who are critically
ill.8,9
Broad-spectrum in vitro activity against
the most common fungal pathogens7,10–12
the most common fungal pathogens7,10–12
Liposomal Amphotericin B has demonstrated
fungicidal activity against Aspergillus fumigatus
and Aspergillus flavus.13
fungicidal activity against Aspergillus fumigatus
and Aspergillus flavus.13
A well-established tolerability and
safety profile6*
safety profile6*
Very common adverse events associated with
Liposomal Amphotericin B treatment include rigors,
pyrexia, hypokalaemia, nausea and vomiting.6
Liposomal Amphotericin B treatment include rigors,
pyrexia, hypokalaemia, nausea and vomiting.6
*Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for detailed information on safety profile.
DAY 0 (continued)
Treatment initiated
DAY 1-5
Treatment continued
